Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics
References (166)
- et al.
Cholecystokinin-induced protection of cultured cortical neurons against glutamate neurotoxicity
Brain Res
(1991) - et al.
A double-blind study with ceruletide in chronic schizophrenic patients: biochemical and clinical results
Psychiatry Res
(1986) - et al.
Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims
Brain Res
(1995) - et al.
Postmortem volume measurements of limbic system and basal ganglia structures in chronic schizophrenics: initial results from a new brain collection
Schizophr Res
(1990) - et al.
Excitatory amino acid projections to the nucleus accumbens septi in the rat: a retrograde transport study utilizing d[3H]aspartate and [3H]GABA
Neuroscience
(1987) - et al.
Cholecystokinin-octapeptide enhances synaptic activity in neurons cultured from rat cerebral cortex
Peptides
(1985) - et al.
Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. 1. evidence for competition with enkephalins for in vitro common degradation pathways
Peptides
(1981) - et al.
The actions of cholecystokinin and related peptides on pyramidal neurones of the mammalian hippocampus
Brain Res
(1981) - et al.
Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia
Molecular Brain Research
(1995) - et al.
Amino acid neurotransmitters and their pathways in the mammalian central nervous system
Neuroscience
(1983)
Limbic pathology in schizophrenia: the entorhinal region- a morphometric study
Biol Psychiatry
Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients
Life Sci
Localization of enkephalin and cholecystokinin immunoreactivities in the perforant path terminal fields of the rat hippocampal formation
Brain Res
Cholecystokinin octapeptide levels in rat brain are changed after subchronic neuroleptic treatment
Eur J Pharmacol
Dual pathways connecting the dorsolateral prefrontal cortex with the hippocampal formation and parahippocampal cortex in the rhesus monkey
Neuroscience
Failure of chronic haloperidol treatment to alter levels of cholecystokinin in the rat brain striatum and olfactory tubercle-nucleus accumbens area
Neuropeptides
[3H]Muscimol binding sites increased in autopsied brains of chronic schizophrenics
Life Sci
Decreased hippocampal expression of a glutamate receptor gene in schizophrenia
Lancet
Localization of cholecystokinin receptors on neuronal elements in rat caudate nucleus
Brain Res
A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing
Neuroscience
Entorhinal-hippocampal connections: a speculative view of their function
Trends Neurosci
Co-localization of GABA and neuropeptides in neocortical neurons
Trends Neurosci
SPECT analysis of regional cerebral blood flow changes in patients with schizophrenia during the Wisconsin Card Sorting Test
Schizophr Res
Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem
Neuroscience
Different modifications of the dopamine metabolism in the core and shell parts of the nucleus accumbens following CCK-A receptor stimulation in the shell region
Neurosci Lett
Effects of dopamine agonists on excitatory inputs to nucleus accumbens neurons from the amygdala: modulatory actions of cholecystokinin
Brain Res
A glutamatergic corticostriatal path?
Brain Res
Corpus callosum lesions increase cholecystokinin concentrations in cortical areas with homeotopic connections
Brain Res
The calibration of 35S or 32P with 14C-labeled brain paste or 14C-plastic standards for quantitative autoradiography using LKB Ultrofilm or Amersham Hyperfilm
Neurosci Lett
Cholecystokinin-octapeptide in chronic schizophrenia: a double-blind placebo-controlled study
Prog Neuropsychopharmacol Biol Psychiatry
Sources of neostriatal cholecystokinin in the cat
J Comp Neurol
Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development
Arch Gen Psychiatry
Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development
Arch Gen Psychiatry
Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics
Arch Gen Psychiatry
Ceruletide: a new drug for the treatment of schizophrenic patients?
Arch Gen Psychiatry
The hippocampus and parahippocampus in schizophrenic, suicide, and control brains
Arch Gen Psychiatry
Abnormal expression of two microtubule-associated proteins (MAP-2 and MAP-5) in specific subfields of the hippocampal formation in schizophrenia
The duality of the cingulate gyrus in monkey: neuroanatomical study and functional hypothesis
Brain
Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics
Arch Gen Psychiatry
Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain
Cereb Cortex
Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics
J Neurosci
Commissural connections of the hippocampal region in the rat, with special reference to their mode of termination
J Comp Neurol
CCK-8 in the treatment of chronic schizophrenia
Psychopharmacol Bull
Zur Neuropathologie der Schizophrenien
Fortschr Neurol Psychiatr
Limbic & paralimbic pathology in schizophrenia: interaction with age- and stress-related factors
Basal ganglia and limbic system pathology in schizophrenia: a morphometric study of brain volume and shrinkage
Arch Gen Psychiatry
Is cholecystokinin therapeutic in chronic schizophrenia?
J Clin Psychiatry
Postmortem evidence of structural brain changes in schizophrenia: differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder
Arch Gen Psychiatry
Cortical neurons expressing the cholecystokinin gene in the rat: distribution in the adult brain, ontogeny, and some of their projections
J Comp Neurol
Quantitative shape analysis of the temporal and prefrontal lobes of schizophrenic patients: a magnetic resonance image study
J Neuropsychiatry Clin Neurosci
Cited by (68)
Regional differences in expression of β-tubulin isoforms in schizophrenia
2012, Schizophrenia ResearchCitation Excerpt :Regionally divergent changes in gene expression are not without precedent. Several other studies have found an increase in various gene expression products in one area, and a decrease in another, suggesting that changes in the brain in schizophrenia are not global, but may be region specific (Bachus et al., 1997; Katsel et al., 2005a, 2005b; Kristiansen et al., 2006; Bauer et al., 2008; Oni-Orisan et al., 2008; Kristiansen et al., 2010). To explore the hypothesis that changes in βI-tubulin are regionally specific, we examined βI-tubulin protein expression in two other regions, the STG and HC.
Anxiogenic effect of CCK8s in the ventral hippocampus of rats: Possible involvement of GABA<inf>A</inf> receptors
2012, Pharmacological ReportsCitation Excerpt :CCK is involved in the regulation of various physiological and cognitive functions such as anxiety, learning and memory, thermoregulation, analgesia and satiety [2]. Cholecystokinin mRNA is decreased in the brain of schizophrenics [1] and its concentration in the brain change during Alzheimer’s disease [23] confirming the active role of CCK in the etiology of psychological disorders. This neuropeptide has an important role in the regulation of anxiety-related behavior [8, 37].
Olanzapine treatment and metabolic dysfunction: A dose response study in female Sprague Dawley rats
2011, Behavioural Brain ResearchCitation Excerpt :An alternative explanation for increased plasma CCK levels may be related to the therapeutic mechanisms by which olanzapine can treat schizophrenia, as decreased CCK may play a role in the disease pathophysiology. For example, schizophrenia patients have low cerebrospinal fluid levels of CCK [83] and decreased CCK mRNA expression in the temporal, frontal and entorhinal cortices [84,85]. Olanzapine treatment had no effect on the level of circulating PYY(3–36), which coincides with findings in male patients [27].
Neuroregulatory peptides of central nervous system origin: From laboratory to clinic
2009, Hormones, Brain and Behavior OnlineEffects of repeated dizocilpine treatment on adult rat behavior after neonatal lesions of the entorhinal cortex
2008, Progress in Neuro-Psychopharmacology and Biological PsychiatryThe CCK-system mediates adaptation to novelty-induced stress in the rat: A pharmacological evidence
2007, Neuroscience Letters